Libido / sexual health peptides
Peptides acting on melanocortin and reproductive pathways; includes one approved agent for a specific indication.
S is approval-grade evidence; F is documented harm or near-zero human data. Each bar is how many peptides on this page land in that tier — a fast read on how much of this category sits in approval-grade evidence versus thin or vendor-driven claims.
The category at a glance
Every compound here ranked S–F by its weighted evidence score — strongest human / approval-grade evidence at the top, thin or vendor-driven claims at the bottom. Tap any row for the evidence read. Popularity never raises a tier.
Receipts, not vendor theater. Every tier here is computed from published evidence and regulatory status — not vendor marketing or influencer claims. See how we score.
SoxytocinStrong human evidenceLow overstatementFDA-approved90/ 100
An FDA-approved hormone (Pitocin) and the most commonly used agent for medical induction and augmentation of labor, backed by a large clinical evidence base. Known safety issues include uterine tachysystole requiring fetal monitoring.
Tier read: strong human evidence · low overstatement risk · low search interest · Approved use. Why not A: supported by human evidence, preclinical depth, mechanism confidence, safety clarity, regulatory clarity, practical relevance.
Read the full oxytocin profile →Bpt-141Strong human evidenceLow overstatementFDA-approved76/ 100
Bremelanotide is a melanocortin-receptor agonist that is FDA-approved (Vyleesi, 2019) for acquired, generalized hypoactive sexual desire disorder in premenopausal women, supported by the RECONNECT phase-3 trials. Approved for a specific indication; nausea and transient blood-pressure effects are documented.
Tier read: strong human evidence · low overstatement risk · low search interest · Approved use. Why not C: supported by human evidence, mechanism confidence, regulatory clarity. Why not A: held back by remaining gaps and limited replication.
Read the full pt-141 profile →DkisspeptinModerate human evidenceLow overstatementResearch-use-only47/ 100
A neuropeptide acting upstream of GnRH to drive LH secretion — an active area of genuine human reproductive-endocrine research rather than an approved drug. Studies probe its role in puberty and reproduction, with possible future clinical applications.
Tier read: moderate human evidence · low overstatement risk · low search interest · Early human. Why not F: supported by mechanism confidence. Why not C: held back by safety clarity, regulatory clarity, practical relevance.
Read the full kisspeptin profile →Dmelanotan-iiEarly human evidenceMedium overstatementResearch-use-only38/ 100
A synthetic non-selective melanocortin agonist used unapproved for tanning and erectile effects, with no approved medical indication. Documented safety concerns include priapism, nausea/flushing, and changes to moles with melanoma case reports.
Tier read: early human evidence · medium overstatement risk · low search interest · Early human. Why not F: supported by mechanism confidence. Why not C: held back by human evidence, safety clarity, regulatory clarity, practical relevance.
Read the full melanotan-ii profile →Libido and sexual-health peptides include one genuinely approved drug and several research compounds. The mechanism matters: PT-141 acts centrally on desire pathways, which is different from blood-flow drugs.
Start with the best-supported options first: pt-141, oxytocin. Then compare them before exploring research-only compounds.
- This libido / sexual health overview (you're here)
- pt-141
- oxytocin
- pt-141 vs oxytocin
- Safety & quality guide
What the evidence actually supports
PT-141 (bremelanotide) is FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women, acting on central melanocortin (MC4R) pathways. Kisspeptin is studied in clinical research as an upstream regulator of the reproductive axis. Oxytocin is approved for obstetric use; its social/behavioral uses are off-label.
Where the hype outruns the data
PT-141 is approved for a specific population and indication, not a universal libido fix; response varies and it has documented side effects. Melanotan-II is unapproved with notable safety concerns and is not a sanctioned tanning method.
FAQ
Is PT-141 FDA-approved?
Yes — bremelanotide (Vyleesi) is approved for HSDD in premenopausal women, with trial support. It is not a universal libido fix.
How is PT-141 different from PDE5 inhibitors?
PT-141 acts centrally on desire pathways; PDE5 inhibitors act peripherally on blood flow.
Is this medical advice?
No — research reference only.
Research reference only. Not medical advice, dosing, or a recommendation to use any compound. “Worth watching” ≠ proven or safe.